Shishijimicin A

From Wikipedia, the free encyclopedia
Shishijimicin A
Shishijimicin A.svg
IUPAC name
Methyl {(1R,4Z,8S,13Z)-8-({6-deoxy-2-O-[2,4-dideoxy-4-(isopropylamino)-3-O-methyl-α-L-threo-pentopyranosyl]-4-C-[(6-hydroxy-9H-β-carbolin-1-yl)carbonyl]-4-S-methyl-4-thio-β-D-galactopyranosyl}oxy)-1-hydroxy-13-[2-(methyltrisulfanyl)ethylidene]-11-oxobicyclo[7.3.1]trideca-4,9-diene-2,6-diyn-10-yl}carbamate
3D model (JSmol)
  • InChI=1S/C46H52N4O12S4/c1-24(2)48-31-23-59-35(21-34(31)57-4)62-40-42(54)46(63-6,41(53)39-37-27(15-18-47-39)28-20-26(51)13-14-30(28)49-37)25(3)60-43(40)61-33-12-10-8-9-11-17-45(56)22-32(52)38(50-44(55)58-5)36(33)29(45)16-19-65-66-64-7/h8-9,13-16,18,20,24-25,31,33-35,40,42-43,48-49,51,54,56H,19,21-23H2,1-7H3,(H,50,55)/b9-8-,29-16-/t25-,31+,33+,34+,35+,40-,42-,43+,45+,46-/m1/s1
Molar mass 981.18 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Shishijimicin A is an enediyne antibiotic isolated from Didemnum proliferum.[1] Isolated in 2003[2] it is part of the family of 10 member ringed enediyne antitumor antibiotic agents, which includes: namenamicin, esperamicin and, calicheamicin. Due to its high potency from cytotoxicity, Shishjimicin A is currently undergoing testing as a possible Antibody-antibiotic Conjugate (ADCs) cancer treatment. Laboratory tests indicate it to be “more than 1,000 times as toxic to cancer cells as the anticancer drug taxol”,[3] also known as Paclitaxel, a prevalent chemotherapy medication. As such, theoretically, only an administration of a minuscule dose of the molecule would be necessary per each treatment. As shishjimicin A supply is scarce and the full extent of its side effects is not yet established, there is still a need for further biological and clinical studies.

Total synthesis[edit]

The total synthesis of shishjimicin A was published by scientists at Rice University in 2015,[4] led by K. C. Nicolaou. Using methodology from the previous isolation of calicheamicin,[5] 21 total steps were conducted for the synthesis,[6][4] briefly outlined below:

  1. Shishijimicin A undergoes deprotection
  2. Trisulfide formation with glycosidation
  3. Carboline disaccharide coupling

The total synthesis includes:[6]

The goal of the synthesis is to create two complex intermediate compounds, trichloroacetimidate and hydroxy enediyne. These will be coupled to produce shishjiimicin A. Though this organic synthesis is challenging, its mapping allows for future contribution to research efforts. Further improvements of the coupling reaction are currently being studied. Practicality and synthesis variations of the complex molecule are essential to working alongside pharmaceutical companies to develop clinical trials and treatment options.

DNA-cleaving mechanism[edit]

The DNA-cleaving mechanism that shishijimicin A

Shishijimicin A binds to the minor groove of double-stranded DNA (DsDNA) and where its β-carboline moiety intercalates into the DNA.[2] The unbound linker regions of DNA in the process of interphase and metaphase are open to binding by binders such as shishijimicin A. These regions lack protective histone proteins throughout the eukaryotic cell cycle. This dsDNA cleavage visualized and low selection probability for sequences by shishijimicin A may attribute to its cytotoxic properties.[2]

Shishijimicin A exhibits IS cytotoxic towards HeLa cells, where the IC50 values are in the range between 1.8-6.9 pM.[7]

See also[edit]


  1. ^ Nicolaou KC, Kiappes JL, Tian W, Gondi VB, Becker J (August 2011). "Synthesis of the carboline disaccharide domain of shishijimicin A". Organic Letters. 13 (15): 3924–3927. doi:10.1021/ol201444t. PMC 3146563. PMID 21711032.
  2. ^ a b c Zhang H, Li R, Ba S, Lu Z, Pitsinos EN, Li T, Nicolaou KC (May 2019). "DNA Binding and Cleavage Modes of Shishijimicin A". Journal of the American Chemical Society. 141 (19): 7842–7852. doi:10.1021/jacs.9b01800. PMID 31050893. S2CID 207196150.
  3. ^ "Rice lab synthesizes cancer-killing compound". TMC News. 2015-07-13. Retrieved 2021-11-29.
  4. ^ a b Nicolaou KC, Lu Z, Li R, Woods JR, Sohn TI (July 2015). "Total Synthesis of Shishijimicin A". Journal of the American Chemical Society. 137 (27): 8716–8719. doi:10.1021/jacs.5b05575. PMID 26133230.
  5. ^ Smith AL, Pitsinos EN, Hwang CK, Mizuno Y, Saimoto H, Scarlato GR, Suzuki T, Nicolaou KC (1993-08-01). "Total synthesis of calicheamicin .gamma.1I. 2. Development of an enantioselective route to (-)-calicheamicinone". Journal of the American Chemical Society. 115 (17): 7612–7624. doi:10.1021/ja00070a005. ISSN 0002-7863.
  6. ^ a b "The Nicolaou Synthesis of Shishijimicin A". Retrieved 2021-11-29.
  7. ^ Oku N, Matsunaga S, Fusetani N (February 2003). "Shishijimicins A-C, novel enediyne antitumor antibiotics from the ascidian Didemnum proliferum(1)". Journal of the American Chemical Society. 125 (8): 2044–2045. doi:10.1021/ja0296780. PMID 12590521.